Article Dans Une Revue Lancet Oncology Année : 2024

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

1 Roswell Park Comprehensive Cancer Center
2 MD Anderson Cancer Center [Houston]
3 North Carolina Central University [Durham]
4 Northwestern University-Robert H Lurie Comprehensive Cancer Center, Chicago
5 Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
6 IGR - Institut Gustave Roussy
7 Département d'hématologie [Gustave Roussy]
8 UNIGE - Université de Genève = University of Geneva
9 UMich - Université du Michigan = University of Michigan [Ann Arbor]
10 Vanderbilt University School of Medicine [Nashville]
11 Mayo Clinic [Rochester]
12 MSSM - Icahn School of Medicine at Mount Sinai [New York]
13 UMB - University of Maryland [Baltimore]
14 Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, USA
15 David Geffen School of Medicine [Los Angeles]
16 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
17 AP-HP - Hopital Saint-Louis [AP-HP]
18 UCBL - Université Claude Bernard Lyon 1
19 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
20 CIRI-LIB - Immuno-Biologie des Lymphomes [CIRI]
21 Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
22 Hôpital Claude Huriez [Lille]
23 SMS - Service des Maladies du Sang [CHU Lille]
24 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
25 CRCI2NA - Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers
26 HUVR - Hospital Universitario Virgen del Rocío [Sevilla]
27 Facultat de Medicina, Universitat Autònoma de Barcelona
28 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli"
29 Kura Oncology, Inc, San Diego
30 HMS - Harvard Medical School [Boston]
Fichier non déposé

Dates et versions

hal-04922787 , version 1 (31-01-2025)

Identifiants

Citer

Eunice Wang, Ghayas Issa, Harry Erba, Jessica Altman, Pau Montesinos, et al.. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncology, 2024, 25 (10), pp.1310-1324. ⟨10.1016/S1470-2045(24)00386-3⟩. ⟨hal-04922787⟩
68 Consultations
0 Téléchargements

Altmetric

Partager

  • More